Floatz logo

Pralsetinib, trans-

Advanced Unresectable or Metastatic Solid Malignancy

Genentech, Inc.Small moleculePhase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
42/ 100
Competitive Position
95/ 100

Competitive context

171 Active assets in the Advanced Unresectable or Metastatic Solid Malignancy cohort.

Asset / SponsorPhaseRating
FLUOROURACILUM
Ruijin Hospital
Phase 4BBB
Eloxatin
Ruijin Hospital
Phase 4BBB
Irinotecan
Eli Lilly and Company
Phase 4BBB
DEXAMETHASONE
Janssen Research & Development, LLC
Phase 2BBB
Ipilimumab
7 Hills Pharma, LLC
Phase 3BB

View all 50 →

Same molecule, other indications

Pralsetinib, trans- is also rated in:

neoplasmDormant
BB
Indicative ·
67 / 100
View asset →
germ cell tumorDormant
BB
Indicative ·
66 / 100
View asset →
respiratory system disorderDormant
BB
Indicative ·
66 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →